The invention provides activatable masked anti-CTLA4 binding proteins (e.g., antibodies, bispecific antibodies, and chimeric receptors) in combination with PD-1 signaling agents inhibitors or PD-Li inhibitors) for use in treating cancer, as well as compositions and kits comprising the activatable masked anti-CTLA4 binding proteins and PD-1 signaling agents.

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

The invention relates to antigen-binding molecules that specifically binds ALPPL2 and/or ALPP but not ALPL or ALPI. It also relates to a pharmaceutical composition, an immunoconjugate and a chimeric antigen receptor comprising said antigen-binding molecules. The invention also relates to methods for reducing the expression or activity of ALPPL2 in a cancer cell and methods of treating a cancer in a subject.

The present disclosure provides Fc domain variants, including effector-competent Fc domain variants. The present disclosure also provides nucleic acids encoding Fc domain variants and host cells for making Fc domain variants. Methods for increasing the yield of Fc domain variants, and methods of using Fc domain variants to treat disease, are also provided.

The instant disclosure provides antibodies and antigen-binding fragments thereof that can bind to a SARS-CoV-2 antigen and, in certain embodiments, are capable of neutralizing a SARS-CoV-2 infection. Also provided are polynucleotides that encode an antibody or antigen-binding fragment, vectors and host cells that comprise a polynucleotide, pharmaceutical compositions, and methods of using the presently disclosed antibodies, antigen-binding fragments, polynucleotides, vectors, host cells, and compositions to treat or diagnose a SARS-CoV-2 infection.

The present invention relates to antibody molecules that bind to Wall Teichoic Acid (WTA) or Capsular Polysaccharides (CP) such as Capsular Polysaccharides type 5 (CP5). The invention relates in particular to antibody molecules of the IgG isotype having a mutation in the Fc domain that enhances clustering of IgG molecules after target binding. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of infectious diseases using these compositions

Disclosed herein are antibodies or antigen binding fragments thereof that bind prostate specific membrane antigen (PSMA), polynucleotides, vectors, host cells, radioconjugates, antibody drug conjugates and methods of treating cancer using the same.

The present invention relates to antibodies which bind to TNFα and comprise a modified Fc region. The antibodies of the invention have improved resistance against proteolytic degradation and good effector functions and/or pharmacokinetic properties.

The invention relates to antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau. The invention also relates to diagnostic, prophylactic and therapeutic methods using anti-tau antibodies.

The present invention relates to polypeptides comprising a mutant human IgG.sub.4, which mutant human IgG.sub.4 is capable of increasing the binding to and activation of immunoreceptor tyrosine-based inhibitory motif (ITIM)-containing FcγRIIb/c (CD32b), but not FcγRIIa (CD32a). More specifically, the invention relates to polypeptides comprising at least one human IgG.sub.4 with a lysine at position 409 (409K), using the EU index according to Kabat et al., which IgG.sub.4 is capable of binding to human CD32b/c with a statistically significant (p=0.05) higher binding affinity than a wild-type human IgG.sub.1 and than a wild-type human IgG.sub.4, for use in the prevention and/or treatment of an autoimmune disease or allergy, as further defined in the claims.